Press Releases May 27, 2026 04:00 PM

MannKind to Present at Jefferies Global Healthcare Conference

MannKind CEO to participate in Jefferies Global Healthcare Conference fireside chat discussing company innovations and strategies.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
MNKD

MannKind Corporation announced that CEO Michael Castagna will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference. The presentation will be webcast live and recorded versions will be available online. MannKind is focused on developing innovative treatments for chronic diseases, including diabetes and pulmonary conditions, leveraging drug-device combination technologies.

MannKind to Present at Jefferies Global Healthcare Conference
MNKD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • MannKind’s CEO will be presenting at a major healthcare industry conference, providing visibility into company strategy and developments.
  • The company focuses on cardiometabolic and orphan lung diseases, addressing unmet needs in diabetes, pulmonary hypertension, and fluid overload.
  • MannKind leverages its expertise in drug-device combinations to develop patient-centric therapies aimed at improving chronic disease management.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that Chief Executive Officer, Michael Castagna, PharmD will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 3 at 9:20 a.m. ET.

Links to the live audio webcast of the presentation will be available on MannKind Corporation’s website at: https://investors.mannkindcorp.com/events-and-presentations. Recorded versions will also be available on the website for approximately 90 days following the conference.

About MannKind
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.

With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.

Learn more at mannkindcorp.com.


Risks

  • Market and regulatory acceptance of MannKind’s innovative therapies remains uncertain, potentially impacting future commercial success.
  • Competition in the biopharmaceutical sector for chronic and rare diseases is intense, posing challenges to market penetration and revenue growth.
  • Technological and operational risks exist in the development and commercialization of drug-device combinations, which could delay or limit product adoption.

More from Press Releases

Trump Media Settles Legal Disputes Jul 19, 2026 GEnx-1B Engines Surpass 50 Million Flight Hours Jul 19, 2026 XA Investments President Kimbery Flynn Speaks to Shareholders About XFLT Proxy Vote Jul 19, 2026 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population Jul 18, 2026 UFC Names Meridian Holdings Official Sponsor of Fight Night Belgrade Jul 18, 2026